Table 2.

Association between antiviral immune responses and disability progression at short, medium, and long term in patients with PPMS

Viruses	Short term	Medium term	Long term
EBV-VCA	HR = 0.997 (0.991–1.003); p = 0.350	HR = 0.999 (0.992–1.006); p = 0.802	HR = 1.001 (0.995–1.007); p = 0.729
EBV-EBNA1	HR = 1.072 (0.981–1.172); p = 0.124	HR = 1.015 (0.945–1.089); p = 0.687	HR = 1.032 (0.959–1.112); p = 0.401
HCMV	HR = 1.002 (0.993–1.011); p = 0.671	HR = 1.008 (0.998–1.018); p = 0.131	HR = 1.000 (0.990–1.011); p = 0.946
HHV-6	HR = 2.043 (0.154–27.022); p = 0.588	HR = 2.830 (0.179–44.770); p = 0.460	HR = 0.623 (0.045–8.580); p = 0.723
Measles	HR = 1.000 (1.000–1.000); p = 0.570	HR = 1.000 (1.000–1.000); p = 0.592	HR = 1.000 (1.000–1.000); p = 0.749

Data are expressed as hazard ratios (HR) and 95% confidence intervals after univariable logistic regression analysis

EBV Epstein–Barr virus, EBNA1 Epstein–Barr nuclear antigen 1, HCMV human cytomegalovirus, HHV-6 human herpesvirus 6, VCA viral capsid antigen